Durolane_header_large_3800x1715

Choose DUROLANE when life won’t wait

  • A single doctor visit.
  • One powerful injection.
  • Up to 26 weeks of pain relief and protection.14

More powerful than Synvisc-One®.‡9 Longer lasting than steroids.10 Already chosen by more than a million doctors and patients worldwide, DUROLANE is a single-injection hyaluronic acid treatment that’s been clinically proven to match the power of 5-injection therapies for pain relief14,17 while significantly improving the quality of life for knee osteoarthritis patients as early as 2 weeks after injection.25,26

Learn more about DUROLANE and how it works.

‡Some patients were treated with a three-injection Synvisc® regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.

 

Durolane_middlesection_2880x1400

Choosing DUROLANE means less time seeking pain relief and more time doing what you love.

Summary of Indications for Use

DUROLANE (3 mL): Argentina, Australia,* Brazil, Chile, Colombia, EU,* India, New Zealand,* Russia, Switzerland,* Turkey,* United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, EU and New Zealand for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Mexico: Symptomatic treatment of mild to moderate knee osteoarthritis.

Taiwan: Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. In addition, DUROLANE has been licensed for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

*DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

Full prescribing information can be found in product labeling.

Summary of risks: You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling.

Summary of Indications for Use for Curavisc: Curavisc (2 mL): EU, Brazil, Egypt, Malaysia: Pain and disturbed function in degenerative and traumatic disease of the joints. Curavisc can be used for large joints, e.g., knee, hip, or shoulder joint. Treatment course of 3- injections, up to 5- injections.

Summary of risks: You should not use CURAVISC if you have infections or skin disease at the injection site. CURAVSIC has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling and on the website at bioventus.com/curavisc.com.